| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.83 [0.67, 1.02] | | < 1 | | 56% | 2 studies (2/-) | 95.9 % | low | not evaluable | high | crucial | - |
| progression or deaths (PFS) | 0.90 [0.73, 1.10] | | < 1 | | 58% | 2 studies (2/-) | 84.8 % | low | not evaluable | high | important | - |
| DCR | 0.89 [0.37, 2.12] | | > 1 | | 89% | 2 studies (2/-) | 39.7 % | low | not evaluable | high | non important | - |
| objective responses (ORR) | 1.65 [0.36, 7.65] | | > 1 | | 77% | 2 studies (2/-) | 73.9 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| STRAE (any grade) | 0.92 [0.65, 1.31] | | < 1 | | 0% | 1 study (1/-) | 67.2 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 1.74 [1.22, 2.47] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 1.58 [0.82, 3.03] | | < 1 | | 0% | 2 studies (2/-) | 8.5 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (any grade) | 1.59 [1.05, 2.41] | | < 1 | | 0% | 1 study (1/-) | 1.5 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 2.21 [1.28, 3.81] | | < 1 | | 0% | 1 study (1/-) | 0.2 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.56 [0.20, 1.61] | | < 1 | | 0% | 2 studies (2/-) | 85.8 % | low | not evaluable | high | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 4.84 [0.59, 39.53] | | < 1 | | 0% | 2 studies (2/-) | 7.2 % | some concern | not evaluable | moderate | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 1.37 [0.12, 15.19] | | < 1 | | 0% | 2 studies (2/-) | 39.9 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.23 [0.00, 13.19] | | < 1 | | 91% | 2 studies (2/-) | 75.9 % | low | not evaluable | high | non important | - |
| Arthralgia TRAE (grade 3-4) | 1.37 [0.12, 15.19] | | < 1 | | 0% | 2 studies (2/-) | 39.9 % | some concern | not evaluable | moderate | non important | - |
| Arthritis TRAE (grade 3-4) | 2.07 [0.21, 20.46] | | < 1 | | 0% | 2 studies (2/-) | 26.9 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.30 [0.01, 10.72] | | < 1 | | 81% | 2 studies (2/-) | 74.3 % | low | not evaluable | high | non important | - |
| Back pain (TRAE grade 3-4) | 0.08 [0.00, 1.64] | | < 1 | | 0% | 1 study (1/-) | 94.7 % | NA | not evaluable | | non important | - |
| Chills TRAE (grade 3-4) | 0.99 [0.03, 29.79] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 10.88 [2.02, 58.51] | | < 1 | | 0% | 2 studies (2/-) | 0.3 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.31 [0.04, 2.19] | | < 1 | | 0% | 2 studies (2/-) | 88.0 % | low | not evaluable | high | non important | - |
| Cough TRAE (grade 3-4) | 0.25 [0.01, 7.42] | | < 1 | | 0% | 1 study (1/-) | 78.6 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 1.50 [0.44, 5.10] | | < 1 | | 0% | 2 studies (2/-) | 25.7 % | low | not evaluable | high | non important | - |
| Dermatitis acneiform TRAE (grade 3-4) | 1.90 [0.06, 56.75] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 11.52 [1.74, 76.27] | | < 1 | | 57% | 2 studies (2/-) | 0.6 % | some concern | not evaluable | moderate | non important | - |
| Dyspepsia TRAE (grade 3-4) | 0.25 [0.01, 7.42] | | < 1 | | 0% | 1 study (1/-) | 78.6 % | NA | not evaluable | | non important | - |
| Dyspnoea TRAE (grade 3-4) | 0.58 [0.33, 1.01] | | < 1 | | 0% | 2 studies (2/-) | 97.4 % | low | not evaluable | high | non important | - |
| Epistaxis TRAE (grade 3-4) | 0.99 [0.03, 29.79] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.52 [0.20, 1.34] | | < 1 | | 0% | 2 studies (2/-) | 91.2 % | low | not evaluable | high | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.16 [0.01, 3.14] | | < 1 | | 0% | 1 study (1/-) | 88.5 % | NA | not evaluable | | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 0.99 [0.03, 29.79] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 2.07 [0.21, 20.46] | | < 1 | | 0% | 2 studies (2/-) | 26.9 % | some concern | not evaluable | moderate | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 1.90 [0.06, 56.75] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 3.00 [0.15, 60.20] | | < 1 | | 0% | 1 study (1/-) | 23.9 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.97 [0.07, 12.71] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Increase AST TRAE (grade 3-4) | 5.73 [0.29, 114.85] | | < 1 | | 0% | 1 study (1/-) | 13.0 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 2.60 [0.64, 10.59] | | < 1 | | 1% | 2 studies (2/-) | 9.2 % | low | not evaluable | high | non important | - |
| Increased lipase level TRAE (grade 3-4) | 3.91 [0.66, 23.24] | | < 1 | | 56% | 2 studies (2/-) | 6.8 % | low | not evaluable | high | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 2.66 [0.28, 25.23] | | < 1 | | 0% | 2 studies (2/-) | 19.8 % | some concern | not evaluable | moderate | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.90 [0.06, 56.75] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Mucosal inflammation TRAE (grade 3-4) | 0.24 [0.01, 5.24] | | < 1 | | 0% | 1 study (1/-) | 81.7 % | NA | not evaluable | | non important | - |
| Myalgia TRAE (grade 3-4) | 1.99 [0.09, 44.45] | | < 1 | | 0% | 1 study (1/-) | 33.3 % | NA | not evaluable | | non important | - |
| Myocarditis TRAE (grade 3-4) | 1.90 [0.06, 56.75] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 3.81 [0.17, 84.75] | | < 1 | | 0% | 1 study (1/-) | 20.2 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.50 [0.04, 7.22] | | < 1 | | 67% | 2 studies (2/-) | 69.1 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.19 [0.01, 4.62] | | < 1 | | 88% | 2 studies (2/-) | 84.4 % | some concern | not evaluable | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 0.99 [0.03, 29.79] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.14 [0.02, 1.29] | | < 1 | | 0% | 2 studies (2/-) | 95.8 % | some concern | not evaluable | moderate | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.99 [0.03, 29.79] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 1.99 [0.09, 44.45] | | < 1 | | 0% | 1 study (1/-) | 33.3 % | NA | not evaluable | | non important | - |
| Pneumonia TRAE (grade 3-4) | 0.84 [0.29, 2.41] | | < 1 | | 0% | 2 studies (2/-) | 62.7 % | low | not evaluable | high | non important | - |
| Pneumonitis TRAE (grade 3-4) | 1.37 [0.12, 15.19] | | < 1 | | 0% | 2 studies (2/-) | 39.9 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 4.15 [0.50, 34.55] | | < 1 | | 0% | 2 studies (2/-) | 9.6 % | some concern | not evaluable | moderate | non important | - |
| Pyrexia TRAE (grade 3-4) | 1.34 [0.14, 12.66] | | < 1 | | 0% | 2 studies (2/-) | 40.1 % | low | not evaluable | high | non important | - |
| Rash TRAE (grade 3-4) | 3.44 [0.40, 29.74] | | < 1 | | 0% | 2 studies (2/-) | 13.2 % | some concern | not evaluable | moderate | non important | - |
| Sepsis TRAE (grade 3-4) | 1.79 [0.30, 10.85] | | < 1 | | 0% | 2 studies (2/-) | 26.4 % | low | not evaluable | high | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.69 [0.06, 7.58] | | < 1 | | 0% | 2 studies (2/-) | 62.0 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.44 [0.06, 3.34] | | < 1 | | 56% | 2 studies (2/-) | 78.5 % | some concern | not evaluable | moderate | non important | - |
| Vomiting TRAE (grade 3-4) | 0.37 [0.04, 3.57] | | < 1 | | 56% | 2 studies (2/-) | 80.2 % | low | not evaluable | high | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.99 [0.09, 11.04] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
